Posted by Michael Wonder on 03 Jul 2024
HAS clarifies the framework of the “bet” on early access to medicines
24 June 2024 - Committed to a process of continuous development of its methods, the High Authority of Health is launching a reflection on its doctrine for assessing applications for authorisations for early access to presumed innovative drugs.
The aim is to better assess the uncertainty surrounding the application and what will subsequently allow it to be removed in order to make the best possible "bet" on the innovative nature of the product, for the benefit of patients.
On this subject, the HAS is publishing a framework note detailing the method of developing this work, expected for the beginning of 2025.
